The Hermiones Meet

As even the most casual Harry Potter fan knows, the new play “Harry Potter and the Cursed Child” is about to take the London theater scene by storm. The show is currently running previews and will open officially on July 30. Recently, one of the stars of the Harry Potter films, Emma Watson, saw the show and had a fun bonding moment backstage.

Watson, who plays Hermione Granger in the films, shared a hug and a chat with Noma Dumezweni, who portrays Hermione in the play. The two had nothing but kind words to say about their meeting, sharing heartfelt photos and sentiments on their social media accounts. Watson said that meeting Dumezweni “was like meeting [her] older self and telling [her] everything was going to be alright” noting that the meeting was “emotional.” Dumezweni couldn’t stop tweeting about the moment, sending out numerous blessings and thanks to Watson.

When asked what she thought of the play, Watson admitted she had no idea what to expect but was blown away by the story. She noted that the play was “beautiful” and that she “felt more connected to Hermione . . . than [she] has since Deathly Hallows came out.”

If you can’t make it to London to take in the play in real life, have no fear. The long anticipated script will be available for purchase the day after “Harry Potter and the Cursed Child” opens on stage.

Seattle Genetics and Clay Siegall Launch New Oncology Treatments

The banner on Seattle Genetics proclaims “Focused on unmet medical needs in oncology”. The company has released a number of new treatments for various cancers since January, 2016. The company is engaged in clinical trials which are posted on its website. The focus is on various lymphomas, leukemia and several solid based tumor types, among other research.

Successful new medications have been developed under the leadership of Clay Siegall. They have received recognition and approval in the United States, Canada and in Europe. Educationally Dr. Siegall‘s background includes a B.S. in Zoology from the University of Maryland. His Ph.D. in Genetics was conferred by George Washington University.

Clay Siegall, PhD. Is a trained scientist. He is giving much needed clinical attention to the development of targeted cancer therapies; Dr. Siegall shows his passion for helping patients as he leads his company in developing therapies for cancers that have received little attention. He is known for scientific innovation through meticulous research and demonstrates high standards in drug development practices.

Dr. Clay Siegall is co-founder of Seattle Genetics as well as being the Preside, CEO and Chairman of the Board of Directors of that same company. In addition he serves on the boards of directors of several other research focused biotechnology companies such as gentyx and Mirna. He is a leader in the field of research and treatment and holds fifteen patents.

Dr. Siegall’s professional history includes the Bristol-Myers Squibb Pharmaceutical Research Institute, the National Cancer Institute, and the National Institutes of Health prior to the founding of Seattle Genetics in 1998. Seventy publications in the medical field list him as an author.

The field of oncology is fortunate to have Clay Siegall involved in working for treatments of underserved diagnoses. His company, Seattle Genetics, does well both in research. It also offers a very profitable investment opportunity. As a leader Dr. Clay Siegall has his steady hand on the research, development and financial aspects of Seattle Genetics. It is a company that will be strong in the future, both in trading and in training and development of future research for the service of people with unmet treatment needs for their cancers.

Read On:

http://www.mirnatherapeutics.com/pdfs/releases/2013%200130%20Mirna%20Siegall%20BOD.pdf

http://www.ultragenyx.com/about/board/siegall/

Gemma Arterton in the West End As Joan of Arc

In case you haven’t heard, BBC is reporting that Gemma Arterton will play Joan of Arc in a production of a famous 1923 play by G.B. Shaw. This is exciting news.

There’s a lot of attention around her fame gained after she starred in 2008’s “Quantum of Solace.” As a huge James Bond admirer, I am excited to see a Bond girl going to the West End. However, she’s so much more than that, and she deserves to be recognized for all she has the potential to do in London theatre over the course of her career. In fact, she has already been on the West End stage before, and recently too.

This artist is continuing to grow as an artist, and it’s only a matter of time before her fame brings her across the Atlantic to Broadway, and around the world. She is a natural presence on the stage in a way that you might not expect from a movie star. She makes you want to be an actor, even if you totally love your desk job…

Most importantly, she has the potential to help a whole generation of young women love theatre, and want to be actors too. There is a real concern in the theatre community of big name movie stars coming over to the stage and taking up leading roles in plays not because they’re talented but because they’re famous. However, in this case, Gemma Arterton is both a famous name and a real talent.

She plays in St. Joan from December 9th to February 18th at the Donmar Warehouse.